You are here

  • Home
  • Archive
  • Volume 32, Issue Suppl 2
  • 2022-RA-1225-ESGO Correlation between the immunocytochemistry of the fallopian tube cells and the pathological findings of the ipsilateral ovary

Article Text

Article menu

Download PDFPDF

Ovarian cancer
2022-RA-1225-ESGO Correlation between the immunocytochemistry of the fallopian tube cells and the pathological findings of the ipsilateral ovary
Free
  1. Sofia Lekka1,
  2. Victoria Psomiadou2,
  3. Theodoros Panoskaltsis3,
  4. Eleni Tsouma4,
  5. Helen Trihia4,
  6. Dimitrios Giannoulopoulos1,
  7. Kalliopi Kokkali1,
  8. Dimitrios Korfias1,
  9. Panagiotis Giannakas1,
  10. Christos Iavazzo1,
  11. Nikolaos Vlahos3 and
  12. George Vorgias1
  1. 1Gynecology, Metaxa Memorial Cancer Hospital, Piraeus, Greece
  2. 2Metaxa Memorial Cancer Hospital, Piraeus, Greece
  3. 32nd Department of Obstetrics and Gynecology, National Kapodistrian University of Athens, Aretaieion Hospital, Athens, Greece
  4. 4Pathology, Metaxa Memorial Cancer Hospital, Piraeus, Greece

Abstract

Introduction/Background Ovarian cancer is the most lethal gynecological malignancy.The high mortality rate is a consequence of delayed diagnosis due to the lack of screening and early diagnostic methods. Based on the recent theory that the majority of the gynecological extrauterine high grade serous carcinomas originate from the fallopian tube, we aimed to evaluate the correlation between epithelial carcinoma of the ovary and the immunocytochemistry of the ipsilateral fallopian tube cells.

Methodology Our research protocol is ongoing and is designed to include at least 115 patients undergoing salpingoophorectomy or total hysterectomy and salpingoophorectomy for any ovarian pathology. Ex vivo fallopian tube cytology smears are obtained utilizing a cytology brush and are placed in both microscopic slides and ThinPrep solution. The fallopian tube cytology samples are classified as benign, atypical or malignant. The cytological samples are also evaluated with immunocytochemistry for p53 protein and PAX-8 biomarker. The pathologic evaluation of the fallopian tubes follows the SEE-Fim protocol.

Results We have collected 40 fallopian tube cytological samples. Among the cases enlisted so far, 42.5% (17/40) refer to malignant ovarian carcinomas (9 HGSC, 2 LGSC, 4 endometrioid, 1 clear cell and 1 non-Hodgkin lymphoma) out of which, 58.8% (10/17) is both p53 and PAX-8 positive, 29.4% (5/17) is negative in immunocytochemistry, whereas 11.7% (2/17) shows positivity in one biomarker only. The benign arm represents the 52.5% of our cases (21/40) and the vast majority 85.7% (18/21) demonstrates negative immunocytochemistry. However, 3 cases of cystadenomas were found positive in p53 protein. Our results in borderline tumors are inconclusive, as the one is positive in both markers and the other negative.

Conclusion The combination of cytology and immunocytochemistry of the fallopian tube smear could be used as a promising diagnostic tool for ovarian, fallopian tube and peritoneal carcinoma. Further evaluation with larger sample size is warranted.

https://doi.org/10.1136/ijgc-2022-ESGO.664

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.